Amadeus Capital Partners has bought a stake in the Amgen and Illumina-backed company through a secondary transaction, valuing it at around $2.4bn.
Venture capital firm Amadeus Capital Partners has paid $24m to acquire shares in Oxford Nanopore, a UK-based DNA sequencing technology developer backed by corporates Amgen and Illumina, in a secondary transaction. The deal valued Oxford Nanopore at roughly $2.4bn, according to the Telegraph, which said Amadeus had bought into the spinout this way after missing…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.